Objectives: We aimed to compare the long-term outcomes of the novel biodegradable polymer cobalt-chromium sirolimus-eluting stent (BP-SES) versus the durable polymer sirolimus-eluting stent (DP-SES) in the I-LOVE-IT2 trial.
cobalt-chromium (CoCr) platform. In the prior reported one-year result of I-LOVE-IT 2 (Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization) trial, the BP-SES was noninferior to the durable-polymer sirolimus-eluting stent (DP-SES) (Firebird2, Microport Medical, Shanghai, China) in the primary composite safety and efficacy endpoint of target-lesion failure (TLF) at 12 months [3] . Nevertheless, long-term data comparing the BP-DES versus the DP-DES are scarce. The purpose of this study was to report the long-term clinical outcomes of patients included in the I-LOVE-IT 2 trial over a 3-year follow-up period.
| M A TE RI A L S A ND M E TH ODS

| Study Design and Patients
The I-LOVE-IT 2 trial (NCT01681381) was a prospective, multicenter, randomized, assessor-blinded, noninferiority study comparing the BP-SES with the DP-SES. Between October 2012 and June 2013, we recruited patients with chronic, stable coronary artery disease, or acute coronary syndromes, including unstable angina, and MI with or without ST-segment elevation at 32 centers in China. Patients were eligible if they were older than 18 years of age and had at least 1 coronary lesion with stenosis >70% in a vessel, with a reference diameter of 2.5-4.0 mm. Patients with multivessel disease were required to undergo complete revascularization within 30 days using the same study stents, if needed. The exclusion criteria were known intolerance to a study drug, metal alloys, or contrast media, life expectancy <1 year, restenotic lesions; prior stent implantation within 1 year, left ventricular ejection fraction <40%, severe renal or hepatic dysfunction, hemodynamic instability, planned surgery within 6 months after an index procedure, childbearing potential within 1 year, and inability to tolerate dual-antiplatelet therapy (DAPT) for 12 months. Patients were randomly assigned to undergo percutaneous coronary intervention (PCI) with either BP-SES or DP-SES, at a 2:1 ratio. The patients who were randomized to the BP-SES group were additionally rerandomized to a 6-or 12-month DAPT group at a 1:1 ratio. Randomization was performed after angiogram by a web-based allocation system. Angiograms were reviewed by a blinded independent core laboratory (CCRF, Beijing, China). The study complied with the provisions of the Declaration of Helsinki, and the study protocol was approved by the institutional review board at each study center. All patients provided written informed consent.
| Procedures
The BP-SES and DP-SES are low-profile, thin-strut CoCr alloy stents that use the same antiproliferative drug [4, 5] (table 1) . Balloon angioplasty and stent implantation were performed, according to standard techniques. Staged procedures, which were defined as procedures planned at the time of the index procedure, were permitted and performed within 30 days, with the same type of study stent. Procedural anticoagulation was achieved with unfractionated heparin at a dose 70-100 IU/kg, and the activated clotting time was maintained at 250 s; the use of glycoprotein IIb/IIIa inhibitors was left to the operator's discretion. A loading dose of 300 mg aspirin and 300 mg clopidogrel was administered before all procedures. All patients were discharged with a prescription for at least 100 mg aspirin indefinitely and 75 mg clopidogrel for a minimum of 6 months after the index procedure.
Qualitative and quantitative coronary angiography, including the
SYNTAX (SYNergy Between Percutaneous Coronary Intervention with
TAXus and Cardiac Surgery) score was centrally evaluated at CCRF using QAngio XA Version 7.3 Analysis Software (Medis Medical Imaging System, Leiden, the Netherlands). [7] . TV-MI was considered in cases in which the MI was related to the target vessel or the MI was not clearly related to another vessel.
ST was categorized using the definitions provided by the Academic Research Consortium. TLR was defined as any repeated percutaneous Values are the mean 6 SD or n (%). Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; AMI, acute myocardial infarction; BP-SES, biodegradable polymer sirolimus-eluting stent; CAD, coronary artery disease; CABG, coronary artery bypass grafting; DP-SES, durable polymer sirolimus-eluting stent; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SYNTAX, SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery; TIMI, thrombolysis in myocardial infarction.
or surgical intervention due to stenosis or occlusion within the stent or within the 5 mm borders proximal or distal to the stent. We regarded revascularization of the target lesion and vessel to be clinically indicated if the stenosis of any target lesion or vessel was at least 50% of the diameter of the vessel, based on quantitative coronary angiography in the presence of objective evidence of ischemia from noninvasive or invasive testing or symptoms. We also regarded revascularization as clinically indicated if stenosis was at least 70% of the diameter of the vessel, regardless of the presence of any ischemic signs or symptoms.
Definite/probable ST was defined using the Academic Research Consortium definition [8] . A bleeding event was defined using the definition of the Bleeding Academic Research Consortium (BARC) for types
Follow-up was performed through telephone or hospital visits at 1, 6, 9, 12, 18, 24, and 36 months, and will continue to undergo follow-up annually for 5 years. All adverse events were adjudicated by a blinded clinical events committee.
| Statistical Analysis
On the basis of previously reported studies, the sample size was calculated expecting a 12-month event rate of 8.3% in both groups. The prespecified noninferiority margin for the primary endpoint was 3.7%.
With a 1-sided type I error of 0.025, 2,631 patients (1,754 and 877 patients in the BP-SES and DP-SES groups, respectively) randomized in a 2:1 ratio would yield at least 90% power to detect noninferiority.
Allowing for up to a 5% loss to follow-up, 2,790 subjects would need to be enrolled. We confirmed that the calculated sample size was enough to assess the noninferiority of the BP-BES to the DP-EES with a 3-year primary endpoint.
The categorical variables are reported as counts and percentages, and between-group differences were assessed with Chi-squared or Fisher exact tests. Continuous variables are presented as the mean and standard deviation and were compared with a two sample t-test. We used time to first event for each type of outcome throughout the study and reported Kaplan-Meier estimates of event rates, and the log-rank test was used to compare between-group differences. A landmark analysis was performed using the 1-year landmark. We prespecified strati- 
| R E SU LTS
A total of 2,737 patients were randomized to treatment with the BP-SES (n 5 1,829) or DP-SES (n 5 908) (Figure 1) . Overall, 45 patients (2.5%) allocated to the BP-SES and 29 (3.2%) allocated to the DP-SES group were lost to follow-up before reaching the 36-month cutoff date, without any between-group differences. Baseline patient characteristics have been previously shown. The two groups of patients were generally well balanced, in terms of their baseline clinical and lesion characteristics ( Table 2) . At 3 years, the incidence of TLF as the primary endpoint was similar between the BP-versus the DP-SES (8.9% vs. 8.6%, P 5 0.81) ( Table   3 , Figure 2A ). The secondary endpoints for the individual components of TLF, including cardiac death, TV-MI, and CI-TLR, were comparable between the two arms and are illustrated in Figure 2B through 2D.
Similarly, there was no difference between two groups in the PoCE (15.2% vs. 14.5%, P 5 0.63) ( Table 3 , Figure 2E ), definite/probable ST (0.8% vs. 1.0%, P 5 0.64) ( Table 3 , Figure 2F ), or any bleeding event (8.9% vs. 10.9%, P 5 0.11).
In a landmark analysis of the primary endpoint and its components, with the cutoff set at 1 year, we found no difference in the late events between 1 and 3 years ( Figure 2 , Table 3 ). The very late ST rates were low, with no significant between-group differences (BP-SES vs. DP-SES, 0.5% vs. 0.5%, P 5 1.00) ( Table 3 , Figure 2F ). The incidence of one-year DAPT cessation was higher for the BP-SES than the DP-SES group (74.5% vs. 69.7%, P 5 0.008), but not significantly different at 3 years (95.7% vs. 94.5%, P 5 0.15) (Figure 3 ).
In the subgroup analysis, the cumulative incidences of TLF were not significantly different between the BP-and DP-SES for any prespe- Multivariate regression analysis showed that lower LVEF, procedural complications (the composite of thrombosis, severe spasm, acute closure, no reflow, dissection, or perforation), or higher baseline SYN-TAX scores were independent predictors for TLF; the latter two factors and lesion length >20 mm were predictors of PoCE, andpostprocedural TIMI flow grade <3 and BMI <23 kg/m 2 were predictors of BARC 3-5 bleeding events through 3 years (Table 4) .
| D ISC USSION
The primary findings of this long-term large-scale, prospective, randomized clinical trial were: (1) The BP-SES was comparable to DP-SES for long-term safety and efficacy outcomes. (2) There was no difference between the BP-and DP-SES by landmark analysis after one year. (3) A jeopardized side branch after PCI, procedural complications, postprocedural TIMI flow grade <3 or higher baseline SYNTAX score were independent risk factors for 3-year TLF. To the best of our knowledge, I-LOVE-IT 2 was the first study that directly compared biodegradable and durable-polymer stents, without any other difference in the stent design, including antiproliferative drug, metal composition or strut thickness.
Both newer generation BP-and DP-DES had showed better safety and efficacy profiles compared with the early generation DES [2] . The rior to the DP-EES for mortality beyond 1 year (HR 2.04, 95% CI 1.27 to 3.35) [12] . However, in a recent meta-analysis including only randomized controlled trials of 14,187 patients, the BP-SES was superior to the DP-DES (60% first-generation, 40% second-generation DES)
in terms of late ST, very late ST and late lumen loss [13] . The inconsistent data among some reports may be due to the multiple differences in stent designs, not only polymer [14] . Notably, the SES used in two arms of our study had similar low-profiles and thin struts (80 lm for the BP-SES vs. 86 lm for the DP-SES), with the same CoCr alloy platform and antiproliferative drug, which ensured that any differences in the results could be attributed only to the polymer used.
Despite the present study, two recent randomized trials have directly compared the thin-strut BP-versus DP-DES and showed a similar safety profile in MI or ST beyond one year [15, 16] . The EVOLVE II trial compared a thin-strut BP-EES with DP-EES in a relatively lower risk PCI cohort of 1,684 patients. At 3 years, the BP-EES was noninferior to the DP-EES, in terms of the primary safety endpoint of death or MI [15] . Similarly, the BIOSCIENCE trial demonstrated a comparable safety and efficacy between the BP-SES and DP-EES that maintained throughout 2-year follow-up [16] . Note that in the present study, the rate of very late ST was low and equivalent (0.5%) for both the BPand DP-SES, and TV-MI occurred in only 0.7% of the patients beyond 1 year, as compared with the high incidence of very late ST in the DP-DES arm of LEADERS (2.5%) [10] . Despite the relative lower complexity of the included lesions (mean baseline SYNTAX score 11.7), the long-term safety benefit of the newer-generation DES seemed to be more attributed to a combination of thinner-strut, improved biocompatibility of the polymer coatings or antiproliferative drug, not the biodegradable polymer.
Although without any difference between groups, the number of bleeding events in our study was higher than the number of thrombotic events, most were nonmajor (BARC type 1-2), and higher than a recent "all-comer" study based on western population [17] . A possible explanation was the so called "East Asian paradox", a phenomenon that states East Asian patients have a similar or even a lower rate of ischemic events after PCI as compared with Caucasian patients [18] . Half of the patients in the BP-SES group received only 6-months of DAPT, Shanghai, China) demonstrated that longer lesion was an independent predictor for 2-year TLF (HR 2.44, 95% CI 1.32-4.53) [20] . One possible explanation is that BP might be less physically robust than DP when pushing DES, particularly in longer lesions. However, this study was not powered to assess differences in the primary endpoint in patients with long lesions, therefore, we cannot exclude the possibility that this finding could be due to chance.
| L I M I TA TI ONS
There are several limitations should be noted. First, only part of the total PCI cohort was enrolled in the study, rather than consecutive patients, and we cannot rule out some selection bias. However, the baseline SYNTAX scores of the enrolled patients in this study were comparable to those in previous trial [10] . Second, the study was powered for the primary composite endpoint of TLF; therefore, our analysis remains underpowered to detect differences in the individual components of the primary endpoint or in rare events, such as ST. Third, we used the old universal definition of periprocedural MI, which may overestimate the occurrence of TV-MI. A recent definition of Society for Cardiovascular Angiography and Interventions was an infarction with >10-fold creatine kinase-myocardial band fraction or >70-fold troponin increases [21] . Finally, half of the BP-SES patients stopped DAPT after 6 months, while most of the DP-SES patients continued with
DAPT until 1 year. This difference might have led to increased ischemic complications in the BP patients. However, because most studies show little/no difference in ischemic endpoints between 6 and 12 months, it is unlikely that early cessation of DAPT played an important role here.
| CON CL U S I ONS
In this prospective, randomized trial, the BP-SES was similar to DP-SES in safety and efficacy outcomes over a 3-year follow-up period. The rate of adverse events beyond 1 year was low and comparable for both treatment arms with a low rate of very late ST. | 615
